NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive to Present at ThinkEquity Partners 4th Annual Growth Conference

SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alexis V. Lukianov, Chairman and Chief Executive Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the ThinkEquity Partners 4th Annual Growth Conference at The Ritz-Carlton Hotel in San Francisco, CA on Wednesday, September 13, 2006 at 9:30 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $2.9 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings -- NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R) -- that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


    Contact:                        Investors:
    Kevin C. O'Boyle                Stephanie Carrington/Nick Laudico
    EVP & Chief Financial Officer   The Ruth Group
    NuVasive, Inc.                  646-536-7017/7030
    858-909-1800                    scarrington@theruthgroup.com
    investorrelations@nuvasive.com  nlaudico@theruthgroup.com

                                    Media:
                                    Jason Rando
                                    The Ruth Group
                                    646-536-7025
                                    jrando@theruthgroup.com

SOURCE
NuVasive, Inc.
09/05/2006

CONTACT:
Kevin C. O'Boyle,
EVP & Chief Financial Officer of NuVasive, Inc.,
1-858-909-1800, investorrelations@nuvasive.com;
or
Investors:
Stephanie Carrington,
1-646-536-7017, scarrington@theruthgroup.com
or
Nick Laudico,
1-646-536-7030, nlaudico@theruthgroup.com,
or
Media:
Jason Rando,
1-646-536-7025, jrando@theruthgroup.com,
all of The Ruth Group